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Background: Fibre intake among North Americans is currently less than half the recommended amount.
Consumers are interested in food products that could promote weight loss and improve health. Consequently,
evaluation of unique fibre sources with potential gut-mediated benefits for metabolic health warrants investigation.
Our objective is to assess the effects of yellow pea fibre supplementation on weight loss and gut microbiota in an
overweight and obese adult population.
Methods/Design: In a double blind, placebo controlled, parallel group study, overweight and obese (BMI = 25-38)
adults will be randomized to either a 15 g/d yellow pea fibre supplemented group or isocaloric placebo group
for 12 weeks (n = 30/group). The primary outcome measure is a change in body fat from baseline to 12 weeks.
Secondary outcomes include glucose tolerance, appetite regulation, serum lipids and inflammatory markers.
Anthropometric data (height, weight, BMI, and waist circumference) and food intake (by 3-day weighed food
records) will be measured at baseline and every 4 weeks thereafter. Subjective ratings of appetite will be recorded
by participants at home on a weekly basis using validated visual analogue scales. At week 0 and at the end of
the study (week 12), an ad libitum lunch buffet protocol for objective food intake measures and dual-energy X-ray
absorptiometry (DXA) scan for body composition will be completed. Participants will be instructed not to
change their exercise habits during the 12 week study. Glucose and insulin will be measured during an oral glucose
tolerance test at weeks 0 and 12. Levels of lipids and CRP will be measured and inflammatory markers (adiponectin,
leptin, TNF-α, IL-6 and IL-8) in the serum will be quantified using Milliplex kits. Mechanisms related to changes in
gut microbiota, serum and fecal water metabolomics will be assessed.
Discussion: Globally the development of functional foods and functional food ingredients are critically needed to
curb the rise in metabolic disease. This project will assess the potential of yellow pea fibre to improve weight
control via gut-mediated changes in metabolic health in overweight and obese adults.
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The impact of obesity is increasingly felt on a global
scale and includes the precipitous rise in co-morbidities
such as type 2 diabetes and hyperlipidemia. In 2008 the
cost associated with obesity and relevant chronic dis-
eases was estimated to be between $4.6 and $7.1 billion
in Canada, depending on the number of chronic diseases
included in the estimation [1]. Of these costs, a large pro-
portion is due to prescription drugs for management of
obesity-related risk factors. For example, in 2004, pharma-
ceutical costs in Canada for lipid-lowering drugs alone
(i.e. one singular risk factor for cardiovascular disease) was
$1.39 billion [2]. In the United States, cardiometabolic risk
factor clusters (including BMI > 25 and two of diabetes,
hyperlipidemia or hypertension) were responsible for na-
tional medical expenditures of $80 billion, of which $27
billion went to prescription drugs [3]. Therefore, there is a
distinct need for solutions for the prevention and manage-
ment of obesity and its related conditions. As opposed to
pharmaceuticals, targeted lifestyle interventions, particu-
larly diet, are the safest and most economic approaches
for the prevention and treatment of obesity-related condi-
tions on a population level, and have the capacity to
achieve multi-faceted health benefits.
Obesity is intimately linked to increased food intake
with both quantitative and qualitative implications. In
particular, fibre is a critical aspect of the diet because of
its beneficial effects on numerous risk factors, including
reducing plasma lipid levels, improving glucose metabol-
ism, and enhancing satiety which helps to reduce food
intake [4]. Current Institute of Medicine recommenda-
tions for dietary fibre intake are 38 g/d for adult males
and 25 g/d for adult females [5]. Unfortunately, data from
national nutrition surveys indicate that dietary fibre intake
is currently significantly below the recommended intake
level [6]. Therefore, interventions directed at increasing
fibre consumption from a variety of sources are needed.
Dietary fibre may also produce unique changes in gut
microbiota, which independently may improve glucose
tolerance, satiety, and lipid metabolism [7]. Different types
of fibre and/or fibre sources may affect metabolic health
in distinct ways, and therefore the diversity of fibre
sources in the food supply is important [8].
Effect of fibre on weight control and glucose tolerance
A great deal of focus has been directed towards elucidat-
ing and evaluating the beneficial metabolic effects of fibre
intake on gut as well as whole-body health in humans
[9,10]. The primary proposed mechanisms for how dietary
fibre (specifically soluble and fermentable fibre) contrib-
utes to improved weight control and insulin sensitivity
include delayed nutrient absorption, stimulation of gut
hormones that regulate food intake and modulation of
gut bacteria.A recent meta-analysis of randomized controlled trials
showed that increased fibre intake, whether from diets
containing foods rich in fibre or soluble fibre supple-
ments, was associated with reduced HbA1c and fasting
plasma glucose in patients with type 2 diabetes [11]. The
improvement in glycemic responses following a high-fibre
meal has also been shown to carry through after a subse-
quent meal, the so-called “second meal effect” [12]. Part of
the beneficial effect of dietary fibre on postprandial glu-
cose control may be related to the release of gut peptides
that influence insulin responses and food intake, such as
glucagon like peptide 1 (GLP-1), peptide YY (PYY) and
ghrelin. For example, feeding the prebiotic fibre oligofruc-
tose for 12 weeks reduced levels of the orexigenic hor-
mone ghrelin and increased levels of the anorexigenic
hormone PYY in overweight adults which corresponded
with lower self-reported energy intake [13]. In the long-
term, these changes in postprandial peptide secretion may
promote weight loss through reductions in ad libitum
food intake.
Role of gut microbiota in obesity and insulin resistance
Members of the Firmicutes and Bacteroidetes phyla rep-
resent the majority of species in the human gut, while
Proteobacteria, Actinobacteria, Chlamydiae, Spirochetes,
and Fusobacteria are present in markedly lower abundance
[14]. The gut microbiota phenotype can be both genetically
and environmentally determined. There is some degree of
genetic influence, because relatives show greater similar-
ities in phylotypes than unrelated individuals even when
these family members live in different environments [15].
However, investigations have largely been targeted towards
determining how microbiota can be environmentally influ-
enced, specifically by disease state and lifestyle interven-
tions. For example, obese individuals have been observed
to have greater proportions of Firmicutes and lesser Bac-
teroidetes [15,16]. A lower proportion of Bacteroidetes has
also been observed as glucose tolerance worsens [17] and
during progression of non-alcoholic steatohepatitis [18].
Both bacterial abundance and composition can be al-
tered with lifestyle changes. Indeed, part of the role of
intestinal bacteria in weight control has been elucidated
through study of patients receiving bariatric surgery. Kong
et al. [19] profiled the gut microbiota of 30 morbidly obese
women before and after receiving Roux-en-Y gastric by-
pass surgery [19]. After the surgery, Bacteroidetes was
increased and Firmicutes and bifidobacteria populations
were reduced. Further, the “richness” (referring to the
number of species present) was greater after surgery, and
the gut microbiota composition correlated more strongly
with white-adipose tissue gene expression compared to
pre-surgery [19]. Weight loss produced via dietary restric-
tion results in an increase in the relative proportion of
Bacteroidetes and a reduction in Firmicutes, such that the
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control subjects [16]. Feeding specific dietary fibres can
also beneficially modulate gut bacteria populations. For
example, in a double-blind placebo-controlled trial in
obese women, feeding 16 g/d inulin and oligofructose
(50/50) vs. placebo (maltodextrin) for 3 months de-
creased Bacteroides, which was associated with a slight
reduction in fat mass [20]. In this study, 1H-NMR was
also performed, but there was no clear clustering effect
of treatment that could be detected for gut microbial
analysis or plasma/urine metabolomic profiles. Indeed,
the specific metabolic function of different bacterial
species is still being elucidated. However, metagenomic
mapping of gut bacteria indicates a highly enriched and
functionally diverse genome related to numerous path-
ways including metabolism of carbohydrates, energy,
amino acids, and vitamins [21].
Part of the beneficial metabolic impact of gut bacteria
has been attributed to the byproducts produced during
fermentation of nondigestible carbohydrates (i.e. dietary
fibre) by these organisms. Short-chain fatty acids (SCFA)
are the primary end-products of carbohydrate fermenta-
tion by gut bacteria, and include acetate, propionate, and
butyrate [22,23]. SCFA are a major energy source for
colonocytes [22]. Recently, it has been discovered that
SCFA are natural ligands for the G-protein coupled re-
ceptor GPR43, which is expressed in numerous tissues
including immune cells, adipocytes, and endocrine cells
[23,24]. While the metabolic implications of SCFA are
still being elucidated, emerging data suggests that the
binding of SCFA to GPR43 may improve glucose toler-
ance and fat metabolism. For example, in primary cul-
ture the binding of SCFA to intestinal GPR43 stimulates
GLP-1 secretion by colonic L cells [25]. In animals, mice
overexpressing GPR43 in adipose tissue remain lean on
a high-fat diet and exhibit lower body weight, white adi-
pose weight, and smaller adipocyte size [26]. In contrast
to wild-type mice, these animals did not develop hepatic
steatosis in response to a high-fat diet and had normal
glucose tolerance. Finally, the GPR43 mice also displayed
greater energy expenditure and increased fat oxidation
[26]. While these findings are preliminary, the implica-
tion is that SCFA may have important effects on the host
organism beyond energy production in the gut.
Pea fibre as a novel and sustainable fibre source
Recently, the interest in pulse crops (e.g. dried beans
and peas) as sources of dietary fibre has increased [27].
Yellow peas are a native Albertan pulse crop [28] with
the potential to have beneficial effects on plasma lipids,
glucose metabolism, and weight control. Pea hulls are
comprised of ~82% fibre making them an excellent
source of dietary fibre that could be incorporated into
food products [29].To date, few studies have examined the metabolic ef-
fects of pea fibre in animal models. Briefly, in rats with
diet-induced glucose intolerance, feeding dry pea seed
coats improved glucose tolerance as well as fasting and
glucose-stimulated insulin levels [30]. Investigation of
skeletal muscle expression of proteins involved in insulin
signaling suggested that pea seed coat consumption
increased glucose transport. Finally, pea seed coat con-
sumption also appeared to reduce markers of oxidative
stress [30]. In hypercholesterolemic Golden Syrian ham-
sters, feeding whole pea flour or fractionated pea flour
(hulls only) did not reduce plasma lipid levels, but de-
creased fasting glucose and insulin concentrations, and
showed a statistical trend towards reducing body fat [31].
More recently, we have demonstrated that yellow pea fibre
reduces glycemia in diet-induced obese rats while yellow
pea flour (rich in pea protein) reduces adiposity (Eslinger
et al., Submitted). Both pea fibre and pea flour reduced
the percent of fecal Firmicutes.
The state of the literature regarding metabolic effects
of pea hull fibre specifically in humans is limited to few
studies. In an acute meal setting, adding pea fibre (10 g)
to a low-fibre (2.8 g) test meal resulted in lower post-
prandial plasma cholesterol levels compared to soybean
fibre in normolipidemic men, but postprandial glucose,
insulin, and plasma triglyceride were not affected by fibre
type [32]. Similarly, isoenergetic high-fibre (26 g) and low-
fibre (9 g) meals produced similar postprandial glucose
and insulin in healthy normal men, however plasma free
fatty acids were better suppressed after the high-fibre meal
which contained pea fibre baked into wheat bread [33].
Conversely, in one study of healthy adults, pea fibre (15 g)
incorporated into a mixed test meal significantly reduced
the postprandial glucose incremental area under the
curve as compared to sugar beet fibre and wheat bran,
while addition of all fibres reduced the postprandial in-
sulin response [34].
As opposed to the effects of acute ingestion of pea
fibre, the metabolic effects of consuming diets contain-
ing foods fortified with pea fibre are also limited to a
few studies. In one study, addition of pea hull fibre to
existing foods (resulting in an average of 3 g/d pea fibre)
increased stool frequency in elderly residents of a long-
term care facility, representing a safe, economical, and
non-invasive alternative to relieve constipation in the
elderly [35]. Feeding young healthy adults a low-fibre diet
or a low-fibre diet supplemented with 33 g/d pea fibre
product (corresponding to 20 g dietary fibre) in a random-
ized cross-over study showed no differences in fasting
cholesterol levels however triglyceride levels in the plasma
and those arising from the liver were reduced in the pea
fibre supplemented group [36]. In addition, incorporation
of the fibre into breakfast and lunch meals resulted in
significantly lower plasma and chylomicron triglyceride
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corporation of whole yellow pea flour into baked products
reduced postprandial glycemia in healthy men and women
compared to products containing whole wheat flour [37].
Finally, in a population who could potentially benefit the
most from dietary fibre provision, providing baked prod-
ucts containing pea fibre (12 g/d of fibre) to overweight
hypercholesterolemic adults for 28d reduced fasting insu-
lin concentrations and improved postprandial glucose re-
sponses after a standardized breakfast meal [38]. Given
the limited state of evidence for the potential benefits of
pea fibre in individuals at-risk for obesity and metabolic
syndrome, clinical trials specifically examining the clinical
outcomes and mechanisms related to pea fibre consump-
tion are warranted.
Specific objectives
This project proposes to perform a comprehensive in-
vestigation of the effects of pea fibre supplementation
on 1) weight loss, 2) glucose control and features of the
metabolic syndrome, 3) food intake and satiety, and 4)
gut microbiota and serum and fecal water metabolites
in free-living overweight and obese adults. The combin-
ation of anthropometric measurements with plasma meta-
bolomics and analysis of fecal microbiota will provide
unique information on the whole-body and in vivo effects
of pea fibre consumption in overweight adults.
Given the research aims, the primary outcome is change
in body fat mass from baseline to 12 weeks. Our second-
ary outcomes include glucose tolerance, serum lipids and
inflammatory markers, and objective and subjective mea-
sures of food intake and appetite. To better understand
the mechanisms by which yellow pea fibre may impact
metabolism, we will also undertake exploratory mechanis-
tic studies on changes in intestinal microbiota and in vivo
metabolism assessed using metabolomics analysis.
It is first hypothesized that the group consuming the
pea fibre will have a greater reduction in body fat com-
pared to the control group. Second, it is predicted that
at follow-up the pea fibre group will have lower fasting
insulin concentrations and reduced glucose and insulin
excursions during an oral glucose tolerance test (OGTT).
Third, it is expected that the pea fibre group will have
greater ratings of fullness and a reduction in ad libitum
energy intake compared to control. Finally, it is antici-
pated that supplementation of pea fibre will beneficially
alter gut microbiota and induce a unique serum and fecal
water metabolite signature reflective of the changes in
body fat mass.
Methods/design
Design, participants, and setting
This study will utilize a double-blind, placebo-controlled,
parallel group design in which 60 overweight and obeseadults (age 18-70 y; BMI 25-38 kg/m2) will be randomized
to either a placebo (n = 30) or pea fibre supplemented
(n = 30; 15 g/d yellow pea fibre) group for 12 weeks.
Randomization will be carried out using computer
generated numbers and stratified according to age, sex,
and BMI.
Adults with a stable body weight for at least 3 months
prior to the study, defined as weight loss or gain of <3 kg
within preceding 3 months to enrollment, will be eligible
to participate. Exclusion criteria include: concomitant use
of any weight loss medication (e.g. Orlistat) or diet/exer-
cise regime designed for weight loss; use of corticoste-
roids, anti-depressants, or anti-epileptic, lipid-lowering,
and diabetes medications; previous bariatric or other in-
testinal surgery; pregnancy or lactation; use of bulk laxa-
tives or probiotic/prebiotic supplements; chronic use of
antacids; use of antibiotics within the preceding 3 months
of enrollment; clinically significant cardiovascular or re-
spiratory disease; liver disease; alcohol or drug depend-
ence; body weight >350 lb; active malignancy; and chronic
infections. Eligibility will be assessed by the researchers
using a screening questionnaire and phone interview.
The overall study design is described in Figure 1, and
the outcome measures are described individually below.
Anthropometric data (weight, BMI, waist circumference)
and food intake (3-day weighed food record) will be col-
lected at baseline and at 4 week intervals. Subjective rat-
ings of appetite will be measured using validated visual
analogue scales (VAS) by the subjects at home on a weekly
basis. At baseline and follow-up (12 weeks), body compos-
ition will be measured by DXA, and an oral glucose
tolerance test will be performed to assess glucose toler-
ance. Plasma inflammatory markers (including TNF-α and
CRP), lipids (total, LDL- and HDL-cholesterol, and tri-
glyceride), and satiety hormones (including GLP-1, PYY,
ghrelin and leptin) will be measured using methods
already established in the laboratory and described below.
Subjects will be provided with an ad libitum lunch buffet
to measure objective food intake. Serum samples will
undergo metabolomics analysis using proton nuclear mag-
netic resonance spectroscopy (1H-NMR) [39]. 1H-NMR
will allow us to measure global metabolic responses which
will complement the plasma biomarkers concurrently
measured. Stool samples will be collected for analysis of
gut microbiota and for fecal water metabolomics using
1H-NMR.
Dietary intervention and novel food product
development
Participants in the active arm of the intervention will
consume biscuits containing 5 g of pea fibre per serving
three times per day, within 30 min of their 3 largest daily
meals. The control group will consume an isocaloric
amount of a control biscuit that is similar in taste and
Figure 1 Overall study design of the fibre supplementation intervention.
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intestinal discomforts associated with a rapid increase in
fibre intake, the dose will be slowly increased during the
first 3 weeks of the study (week 1 = 5 g/d; week 2 = 10 g/d;
week 3 = 15 g/d). The biscuits will be formulated with a
low energy content and will be designed and produced at
the Food Processing Development Center of Alberta Agri-
culture and Rural Development (Leduc, AB). Biscuits will
be produced in Leduc and shipped to Calgary. Each sub-
ject will record the time the product was consumed on a
calendar provided by the investigators. Subjects will be
instructed to return all biscuit packages and any uncon-
sumed biscuits for counting to assess compliance and
actual intake. Subjects will maintain their ad libitum ha-
bitual food intake during the intervention, which will be
monitored via completion of monthly 3-day weighed food
records. The study is designed to examine the effects of
pea hull fibre supplementation in a real-life setting, inde-
pendent of any other diet or exercise intervention; there-
fore, subjects will be encouraged to maintain their regular
lifestyle, to eat until comfortably full and not to con-
sciously try to gain or lose weight throughout the study.
At the end of the study an informal interview will be con-
ducted to assess whether or not the subjects remained un-
aware of the treatment they received.
Laboratory analyses and outcome measurements
Anthropometrics and dual X-ray absorptiometry
Height, weight, BMI, and waist circumference will be
measured at baseline and every 4 weeks thereafter dur-
ing clinical visits with research staff. Body weight will be
measured using a standard balance beam scale. Waist cir-
cumference will be measured at the level of the umbilicus
using a tape measure by the same research staff member at
all visits. Percent fat mass and lean mass will be measured
using a whole body dual-energy x-ray absorptiometry
(DXA) scan (Hologic QDR 4500, Hologic, Inc., Bedford,
MA, USA). These results will be used in conjunction withHologic QDR software to determine lean mass, bone min-
eral content and fat mass. Bone mineral density (BMD)
and percent fat will also be determined.
Food record
Food and beverage intake will be assessed using 3-day
weighed food records at baseline and every four weeks
thereafter using food scales and standardized forms pro-
vided to the subjects. As described above, subjects will
not be prescribed specific diets and will instead be en-
couraged to maintain their habitual intake. Prior to the
start of the study all subjects will attend a training ses-
sion delivered by a Registered Dietitian in which they
will be instructed on the use of the food scale and how to
record their food intake. Subjects will then be instructed
to weigh and record all food consumed for 2 weekdays
and 1 weekend day. This information will be analyzed
with FoodWorks software (The Nutrition Company, Long
Valley, NJ). Participants will be instructed to maintain
their current level of physical activity throughout the
study. Physical activity will be monitored using the
Godin’s Leisure Time Exercise Questionnaire which will
be completed at baseline, 4, 8 and 12 weeks.
Subjective and objective assessments of appetite
Subjective ratings of appetite will be recorded by partici-
pants at home on a weekly basis using a validated 100 mm
VAS [40,41]. The questions are:
1) “How hungry do you feel?” anchored by “I am not
hungry at all” and “I have never been more hungry”.
2) “How satisfied do you feel?” anchored by “I am
completely empty” and “I cannot eat another bite”.
3) “How strong is your desire to eat” anchored by “I
have no desire to eat” and “I have a great desire
to eat”.
4) “How full do you feel?” anchored by “Not at all full”
and “Totally full”.
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by “Nothing at all” and “A lot”.
At baseline and end of the study (week 12), an ad libi-
tum lunch buffet protocol will be performed to object-
ively assess food intake. This buffet-style provision of
foods has been shown to be highly reproducible for the
measurement of energy intake and macronutrient prefer-
ences [42-44]. The ad libitum lunch will be served fol-
lowing the OGTT (3 hours after taking the oral glucose
drink). The subjects will be instructed to eat until "com-
fortable satisfaction," and each subject's energy intake
will be measured. Conversation between subjects will be
monitored such that normal conversation will be allowed
as long as the topics do not involve food, appetite, or
related issues [43]. The lunch will consist of two food
choices. The first will be a savory food (i.e. cheese pizza)
and the second a sweet food (i.e. cookies) [45,46]. The en-
ergy content of the food choices will be pre-determined,
and subjects will be given a pre-weighed amount of the
two choices and allowed to eat until satisfied. Though the
food quantity will be pre-determined, each item will be
provided in an amount corresponding to a reasonable sur-
plus, so no researcher-imposed limit is placed on the sub-
ject’s consumption. Upon meal completion, the remaining
food not consumed by the subjects will be weighed by re-
search staff. Subjective ratings of appetite using the VAS
will be collected immediately before and after the ad libi-
tum meal. The acceptability of the meal will be assessed
with the following question, “How acceptable or pleasing
did you find the meal?” anchored by “Not at all accept-
able” and “Highly acceptable”.Oral glucose tolerance test
At baseline (day 0) and follow-up (wk 12) after an over-
night fast, glucose tolerance will be assessed with an
OGTT. A cannula will be inserted into the antecubital
vein to allow for repeated blood draws. Following an
overnight fast, a baseline blood sample will be drawn.
Subjects will be given a 75 g oral glucose drink and add-
itional blood samples taken at time = 30, 60, 120 and
180 minutes by registered nurses. Blood will be centri-
fuged and plasma frozen at -80°C for subsequent ana-
lyses. Glucose will be quantified using a glucose trinder
assay (Stan Bio, Boerne, TX, USA).Plasma lipids and inflammatory markers
At baseline and follow-up a fasting blood sample will be
taken for measurement of plasma HbA1c, lipids and CRP.
Samples will be sent to Calgary Laboratory Services for
analysis. Serum inflammatory markers (adiponectin, lep-
tin, TNF-α, IL-6 and IL-8) will be quantified using Milli-
plex kits (Millipore, Billerica, MA, USA).Satiety hormones
At each of the five time points during the OGTT, add-
itional blood samples will be collected for measurement
of satiety hormones. Blood will be drawn into a cooled
EDTA vacutainer tube containing diprotinin-A (0.034 mg/
ml blood; MP Biomedicals, Irvine, CA); Sigma protease
inhibitor (1 mg/ml blood; Sigma Aldrich, Oakville, ON,
Canada) and Roche Pefabloc (1 mg/ml of blood; Roche,
Mississauga, ON, Canada) [13]. Blood will be centrifuged
within 30 min and plasma analyzed for ghrelin (active), in-
sulin, leptin, glucose-dependent insulinotropic polypeptide
(GIP) (total), GLP-1 (active), and PYY (total) concentra-
tions using a Human Gut Hormone Panel Milliplex Kit
(Millipore, St Charles, MO).
Gut microbiota
Stool will be collected at baseline and follow-up for ana-
lysis of gut microbiota. Subjects will be instructed on
proper methods for stool sample collection and all mate-
rials will be provided in a convenient specimen collec-
tion kit. Each subject will collect 2 tablespoons of stool
into a pre-labeled sterile container. The container will
be sealed, placed in a biohazard bag, and immediately
stored in a standard home freezer (-20C). The specimen
will be transported to our research lab within 4 days of
collection in a styrofoam container on an ice pack.
For analysis of gut bacteria species, total bacterial DNA
will be extracted from the frozen fecal samples using the
QIAamp DNA Stool Mini Kit (Qiagen, Mississauga, ON).
Bacterial DNA concentrations will be measured using the
Pico-Green DNA Quantification Kit (Invitrogen, Carlsbad,
CA). Microbiota will be quantified using quantitative PCR
according to our previous work [47] using the BioRad
iCycler (BioRad Inc., Mississauga, ON) and group-specific
primers. Briefly, amplification and detection will be con-
ducted in 96-well plates with SYBR Green 2 × qPCR
Master Mix (BioRad). Group specific primers have been
previously published [47]. The 16S rRNA gene copies
value will be calculated according the following web-
page: http://cels.uri.edu/gsc/cndna.html using average
genome sizes. Standard curves will be normalized to the
copy number of the 16S rRNA gene obtained from the fol-
lowing webpage: http://rrndb.umms.med.umich.edu/.
Serum metabolomics
Metabolomics analysis provides a snapshot of an organ-
ism’s current metabolic profile. Beyond measurement of
single metabolites, applying principal component analysis
(PCA) to metabolomics data allows for the relationships
between variables to be determined, thereby identifying a
metabolic signature [48]. Sample preparation and meta-
bolomics analysis will be performed according to our
previous work [39]. Briefly, following sample prepar-
ation, including filtering and pH standardization, all
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600 spectrometer (Bruker Biospin, Milton, Canada). Proc-
essed spectra will be imported into Chenomx NMR Suite
software (Edmonton, AB) for metabolite identification and
quantification. In order to describe the metabolite changes
in the context of other physiological variables, metabolo-
mic data will be integrated with the other biological
variables assessed (blood biochemistry, satiety hormones,
body composition) using O2PLS-DA (orthogonal partial
least squares discriminatory analysis) modeling [39,49].
Fecal water metabolomics
The fecal samples collected at baseline and 12 weeks
will be used for fecal water 1H-NMR metabolomic ana-
lysis. The NMR sample preparation protocol will be
based on previously published work that has been shown
to maximize retrieval of SCFAs from the fecal samples
[50]. 1H-NMR spectra will be acquired on a Bruker Ad-
vance 600 spectrometer (Bruker Biospin, Milton, Canada)
operating at 600.22 MHz, and multivariate analysis of
metabolic profiles will be performed using SIMCA-P +
12.0.1 software (Umetrics). The PCA and O-PLS-DA
models of the fecal water extracts are expected to show
separation between the control and pea fibre groups
based on metabolite concentrations involved in gut micro-
biota activity resulting from fibre fermentation.
Sample size calculation
Sample size was calculated based on anticipated changes
in body fat using data from our previous study of pre-
biotic fibre supplementation in overweight and obese
adults [13]. The expected change in body fat in the pulse
fibre group is -1.11 kg whereas the expected weight change
in the control group is +0.20 kg, with a standard deviation
of ±1.6 kg. Assuming an alpha = 0.05 and power = 0.80
(80%) we would need to recruit 24 subjects in each study
arm. An additional 6 patients per group will be added to
account for the expected 20% loss to follow up for a total
of 30 patients per group.
Statistical analysis
Data will be analyzed using SPSS statistical program (IBM
Software, Armonk, NY) with results considered statisti-
cally significant (2-sided) at P ≤ 0.05. Values with skewed
distribution will be logarithmically transformed prior to
analysis. Baseline characteristics will be compared be-
tween groups using chi-square for categorical variables
and t tests for continuous variables. Primary analysis
will be performed on an intent-to-treat basis, regardless
of subject compliance. The primary outcome measure is
change from baseline to 12 weeks in body fat. ANCOVA,
with testing for confounding factors (sex) and potential
covariates (BMI, age) will be used to assess the difference
between groups at weeks 0 and 12. Should the main effectof diet be significant, Tukey’s multiple comparison test will
be used. Secondary outcomes measured at 0 to 12 weeks
(e.g. satiety hormones, glycemia, insulinemia, food intake)
will be analyzed with ANCOVA as above. For variables
measured over time (e.g. body weight, satiety hormones
and glucose at 0, 30, 60, 120 and 180 minutes), a mixed
model of repeated measures ANCOVA will be applied to
examine the effect of treatment, time and their inter-
action. Our planned secondary analysis will be per
protocol with all subjects who complete the 12 week
intervention and are compliant based on consumption
of ≥80% the product doses. Cases with missing outcome
data will be excluded from analysis.
For metabolomics analysis, in addition to univariate tests,
multivariate analysis will conducted using SIMCA-P +
12.0.1 software (Umetrics, Sweden). Data will be repro-
cessed by mean-centering and unit variance scaling. A
supervised partial least squares discriminant analysis (PLS-
DA) approach will be used to compare the variance of me-
tabolite concentrations between the two sample classes
(diet: control and pea fibre). A supervised orthogonal par-
tial least squares analysis will be used (control versus pea
fibre) for a direct comparison of the variance between diet
type (Y variable) and metabolite concentrations (X vari-
able). The results from the metabolomics analysis will also
be combined with the plasma satiety hormones and other
biological measurements and regressed to the diet type
using O2-PLS-DA (orthogonal PLS-DA).
Ethics
This proposal has been approved by the Conjoint Health
Research Ethics Board of the University of Calgary. Vol-
untary, written informed consent will be obtained from
each participant.
Discussion
The proposed study will determine whether increased
consumption of fibre derived from yellow peas enhances
weight loss and specifically body fat loss compared to
control. In addition, the effect of pea fibre on glucose tol-
erance, appetite, serum lipids and inflammatory markers
will also be determined. Mechanisms related to changes in
gut microbiota and serum and fecal water metabolites will
be examined. The goal of this research is to provide
evidence for the potential role of pulse-derived fibre in
weight management. This work is important in light of
the growing interest by consumers, food manufacturers
and health care professionals in functional foods that im-
pact long-term health.
The global functional food market has expanded sub-
stantially in recent years, and is expected to continue
growing in the coming years [51,52]. For example, from
2000 to 2006 the global functional food market in-
creased by 68% [51]. This growing market for functional
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nesses that in 2004 generated annual revenues of $2.9
billion and exported $545 million worth of products in
Canada alone [53]. As compared to drug development,
functional food development has the advantages of shorter
development periods and lower development costs [54].
Development of the functional food product sector is
beneficial for consumers, the agri-food sector, and public
health [51,54]. Indeed, a significant proportion of research
and development in major food companies is directed to-
wards developing “healthful” foods [55]. In particular, food
products aimed at gut health dominate the functional food
markets in Japan and Europe, including both probiotic-
and prebiotic-fortified foods [54].
In the current study, pulse fibre will be incorporated
into a cookie-type biscuit that will be consumed 30 mi-
nutes prior to a meal, thereby acting as a meal pre-load.
Consuming the biscuit between meals has implications
for snacking behaviors and potential new snack foods.
Modifying snack options presents a key area to expand
research in dietary supplements as snacking is prevalent
[56]. Not only does snacking displace healthy nutrient-
dense foods but the energy density of snacks has also in-
creased over time such that the contribution of snacking
to overall energy intake is substantial (24% by one estima-
tion) [56,57]. However, snacking is not necessarily a nega-
tive eating behavior, because it depends on food choices.
For example, one study found that high-frequency snack
consumption occurred in individuals with both healthy
and unhealthy dietary patterns [58]. Given the increased
prevalence of snacking in combination with the increase
in food consumption away from home and desire for
convenient food products [59,60], snack foods represent
an ideal behavior to modify by replacing currently con-
sumed food options with more nutrient-dense options
that are attractive and palatable, and that also have the
potential to positively affect health outcomes. Ideal
snacks would be those which are healthy and balanced
in macronutrient proportions; provide functional nutri-
ents that individuals may not otherwise consume; and are
portable without requirement for preparatory methods, so
they can be incorporated easily into daily consumption at
home or work.
Ultimately, this project will determine whether yellow
pea fibre has the potential to be incorporated as a func-
tional food ingredient in products aimed at weight man-
agement and metabolic health.Abbreviations
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